NCT03988465

Brief Summary

This study will evaluate the performance of the Quantra System comprised of the Quantra Hemostasis Analyzer with the Quantra QPlus Cartridge in patients undergoing cardiac surgery utilizing cardiopulmonary bypass, including the placement of a ventricular access device.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jun 2019

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 10, 2019

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 17, 2019

Completed
2 days until next milestone

Study Start

First participant enrolled

June 19, 2019

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 13, 2020

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 15, 2020

Completed
Last Updated

July 1, 2020

Status Verified

June 1, 2020

Enrollment Period

9 months

First QC Date

June 10, 2019

Last Update Submit

June 30, 2020

Conditions

Keywords

Viscoelastic testingCoagulationQuantraHemostasis

Outcome Measures

Primary Outcomes (15)

  • Comparison of Quantra Clot Time results to TEG R results

    Coagulation function assessed by Quantra and TEG 5000

    Baseline, defined as after induction of anesthesia but before surgical incision

  • Comparison of Quantra Clot Stiffness results to TEG MA results

    Coagulation function assessed by Quantra and TEG 5000

    Baseline, defined as after induction of anesthesia but before surgical incision

  • Comparison of Quantra Clot Time results to TEG R results

    Coagulation function assessed by Quantra and TEG 5000

    During bypass

  • Comparison of Quantra Clot Stiffness results to TEG MA results

    Coagulation function assessed by Quantra and TEG 5000

    During bypass

  • Comparison of Quantra Clot Time results to TEG R results

    Coagulation function assessed by Quantra and TEG 5000

    Post-bypass, defined as 10 to 20 minutes after protamine administration

  • Comparison of Quantra Clot Stiffness results to TEG MA results

    Coagulation function assessed by Quantra and TEG 5000

    Post-bypass, defined as 10 to 20 minutes after protamine administration

  • Comparison of Quantra Clot Time results to standard coagulation test results (aPTT)

    Coagulation function assessed by Quantra and standard coagulation tests

    Baseline, defined as after induction of anesthesia but before surgical incision

  • Comparison of Quantra Clot Stiffness results to laboratory fibrinogen results

    Coagulation function assessed by Quantra and standard coagulation tests

    Baseline, defined as after induction of anesthesia but before surgical incision

  • Comparison of Quantra Clot Stiffness results to laboratory-determined platelet count

    Coagulation function assessed by Quantra and standard coagulation tests

    Baseline, defined as after induction of anesthesia but before surgical incision

  • Comparison of Quantra Clot Time results to standard coagulation test results (aPTT)

    Coagulation function assessed by Quantra and standard coagulation tests

    During bypass

  • Comparison of Quantra Clot Stiffness results to laboratory fibrinogen results

    Coagulation function assessed by Quantra and standard coagulation tests

    During bypass

  • Comparison of Quantra Clot Stiffness results to laboratory-determined platelet count

    Coagulation function assessed by Quantra and standard coagulation tests

    During bypass

  • Comparison of Quantra Clot Time results to standard coagulation test results (aPTT)

    Coagulation function assessed by Quantra and standard coagulation tests

    Post-bypass, defined as 10 to 20 minutes after protamine administration

  • Comparison of Quantra Clot Stiffness results to laboratory fibrinogen results

    Coagulation function assessed by Quantra and standard coagulation tests

    Post-bypass, 10 to 20 minutes after protamine

  • Comparison of Quantra Clot Stiffness results to laboratory-determined platelet count

    Coagulation function assessed by Quantra and standard coagulation tests

    Post-bypass, defined as 10 to 20 minutes after protamine administration

Study Arms (1)

Cardiac Surgery Patients

Patients undergoing cardiopulmonary bypass surgery, including placement of a ventricular access device.

Diagnostic Test: Quantra System

Interventions

Quantra SystemDIAGNOSTIC_TEST

Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.

Also known as: Quantra QPlus Cartridge
Cardiac Surgery Patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population includes subjects 18 years or older undergoing cardiac surgery utilizing cardiopulmonary bypass, including placement of a ventricular access device.

You may qualify if:

  • Subject is ≥ 18 years
  • Subject is scheduled for cardiac surgery utilizing cardiopulmonary bypass, including the placement of a ventricular access device.
  • Subject is willing to participate, and he/she has signed a consent form.

You may not qualify if:

  • Subject is younger than 18 years
  • Subject is unable to provide written informed consent
  • Subject is incarcerated at the time of the study
  • Subject is pregnant
  • Subject is currently enrolled in a distinct study that might confound the results of the proposed study
  • Subject is affected by a condition that, in the opinion of the clinical team, may pose additional risks

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Texas Medical Branch

Galveston, Texas, 77555, United States

Location

MeSH Terms

Conditions

Blood Loss, SurgicalThrombosis

Condition Hierarchy (Ancestors)

HemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsIntraoperative ComplicationsEmbolism and ThrombosisVascular DiseasesCardiovascular Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 10, 2019

First Posted

June 17, 2019

Study Start

June 19, 2019

Primary Completion

March 13, 2020

Study Completion

May 15, 2020

Last Updated

July 1, 2020

Record last verified: 2020-06

Data Sharing

IPD Sharing
Will not share

Locations